Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

3,919 total articles

FDA Moves to Curb Use of GLP-1 Ingredients in Unapproved Compounded Drugs

FDA Moves to Curb Use of GLP-1 Ingredients in Unapproved Compounded Drugs

The U.S. Food and Drug Administration announced plans to restrict use of GLP-1 ingredients in compounded drugs that lack FDA approval, highlighting safety, quality and legal issues. The action follows marketing of such compounded copies by telehealth and compounding firms and coincides with a nearly 12% after-hours drop in Hims & Hers Health shares…

Hennessy Capital Investment Corp. VIII Raises $241.5 Million in SPAC IPO

Hennessy Capital Investment Corp. VIII Raises $241.5 Million in SPAC IPO

Hennessy Capital Investment Corp. VIII completed an initial public offering that generated $241.5 million from the sale of 24.15 million units at $10.00 apiece, including 3.15 million units issued via the underwriters' full over-allotment exercise. The SPAC began trading on Feb. 5, 2026, with proceeds held in trust as it searches for a target, with…

Vista Leads $350M-plus Round in SambaNova as Intel Joins Funding Push

Vista Leads $350M-plus Round in SambaNova as Intel Joins Funding Push

Vista Equity Partners is heading a new Series E financing round of more than $350 million in AI chip maker SambaNova Systems, in partnership with Cambium Capital, with Intel expected to commit roughly $100 million and potential for up to $150 million. The fundraising is intended to support SambaNova's push into inference chips and cloud services as…

Dow Jones Tops 50,000 as Blue-Chip Stocks Lead a Broad Rally

Dow Jones Tops 50,000 as Blue-Chip Stocks Lead a Broad Rally

The Dow Jones Industrial Average exceeded 50,000 for the first time on Friday, propelled by gains in blue-chip names. The 30-stock benchmark rose 2.2% to 50,011 by mid-afternoon in New York, marking a year-to-date increase of 4% that outpaces other major U.S. equity indexes. The S&P 500 and Nasdaq remain below their peak levels after a recent pullb…

Agomab Therapeutics Begins Nasdaq Trading Below IPO Price

Agomab Therapeutics Begins Nasdaq Trading Below IPO Price

Agomab Therapeutics NV started trading on the Nasdaq Global Select Market at $14.70 per share, below its $16.00 initial public offering price. The company priced 12,500,000 American Depositary Shares at $16.00 each, with expected gross proceeds of $200.0 million before fees. Underwriters have a 30-day option to buy an additional 1,875,000 ADSs. The…

Moody's Elevates AbbVie to A2, Assigns Stable Outlook

Moody's Elevates AbbVie to A2, Assigns Stable Outlook

Moody's Ratings raised AbbVie's senior credit rating to A2 from A3 and lifted related debt short-term ratings, citing robust performance in the company's immunology and neuroscience franchises. The agency revised AbbVie's outlook to stable from positive, highlighting continued above-peer earnings growth despite Humira's patent expiration pressures …

Moody's Keeps Coty at Ba1 but Shifts Outlook to Negative

Moody's Keeps Coty at Ba1 but Shifts Outlook to Negative

Moody's has affirmed Coty Inc.'s Ba1 corporate family rating but moved the outlook from stable to negative after the beauty company reported weaker-than-anticipated operating performance. While Moody's highlighted Coty's ability to generate free cash flow and potential interest-cost relief from debt paydown tied to the Wella sale, the rating agency…